arGEN-X appoints Alain Thibault as its new chief medical officer
pharmafile | March 19, 2012 | Appointment | Sales and Marketing | Alain Thibault, Regeneron, arGEN-X
arGEN-X, a biopharma firm focused on the discovery and development of human monoclonal antibodies, has appointed Alain Thibault as the company’s chief medical officer.
Dr Alain Thibault has gained a wealth of clinical development experience in oncology, both in the US and Europe, in a career spanning more than 15 years.
Prior to joining arGEN-X, Thibault was therapeutic area head of oncology at Regeneron where he was responsible for clinical development, product strategy and portfolio management, as well as co-ordination of the collaboration with Sanofi to develop fully human antibody products for multiple cancer indications.
While at Regeneron, Thibault led the clinical development of the VEGF Trap Eylea (aflibercept).
Thibault has extensive clinical development expertise across all stages of biopharmaceutical clinical development, having previously held senior research positions at Johnson & Johnson Roche before joining Regeneron.
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …

Dupixent approved as first biologic medicine in Japan for COPD patients
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of …






